INTEGRA LIFESCIENCES HOLDINGS CORP (IART) Integra LifeSciences Holdings Corporation is a medical technology company focused on the creation, production, and global distribution of advanced surgical implants and instruments. These products are utilized across various medical fields, including neurosurgery, limb reconstruction, and general surgical procedures. The company operates through two primary business segments: Codman Specialty Surgical and Tissue Technologies. The Codman Specialty Surgical division offers a comprehensive range of neurosurgical and neuro-critical care products. This includes specialized equipment for tissue ablation, dural repair solutions, cerebral spinal fluid management systems, intracranial monitoring tools, and cranial stabilization devices. Additionally, this segment provides surgical headlamps, various instrumentation, and supports these offerings with asset management software, technical assistance, and after-market services. Integra also supplies an extensive catalog of approximately 40,000 surgical instrument designs, along with a wide selection of surgical and lighting products. Its clientele spans hospitals, surgical centers, and extends to dental, podiatry, and veterinary practices. The Tissue Technologies segment specializes in innovative regenerative technology products for the treatment of both acute and chronic wounds. It further provides surgical tissue repair solutions for a multitude of applications, such as hernia repair, peripheral nerve protection and regeneration, and tendon reconstruction. This encompasses a broad array of offerings for skin and wound repair, plastic and reconstructive surgery products, bone grafting materials, and specialized nerve and tendon repair products. Integra LifeSciences distributes its diverse product portfolio internationally, reaching markets throughout the United States, Europe, Asia Pacific, and other global regions. Distribution is managed directly through its dedicated sales forces and various other channels, serving a wide array of healthcare entities including hospitals, integrated health networks, group purchasing organizations, individual clinicians, surgery centers, and other healthcare providers. Founded in 1989, Integra LifeSciences Holdings Corporation is headquartered in Princeton, New Jersey.
Sector: Surgical & Medical Instruments & Apparatus
Industry: Medical - Devices
Integra LifeSciences Holdings Corporation NASDAQ:IART Healthcare · Medical - Devices
Mkt Cap $991.96M
Vol 0
$ Vol 0
RVOL 0
Earnings 0
Press Release
Integra LifeSciences to Highlight Hands-On Education and Neurosurgery Innovation at CNS 2026 Annual Meeting
Integra LifeSciences announced its participation in the 2026 CNS Annual Meeting (Oct 31-Nov 4, Washington, D.C.), showcasing its neurosurgery portfolio at Booth 341.
The company will offer hands-on training and interactive education featuring key products including the Aurora Surgiscope System, CUSA Clarity Ultrasonic Surgical Aspirator, DuraGen/Durepair dural repair matrices, and ICP monitoring solutions.
The release is promotional in nature, highlighting portfolio breadth (neurocritical care, CSF management, dural repair, visualization, tissue resection) rather than disclosing new financial or clinical results. CUSA Clarity is noted as celebrating 20 years in Integra's portfolio.
• 2d ago AI analysis › Press Release ⚠ 5
Integra LifeSciences Reports Third Quarter 2026 Financial Results
Integra LifeSciences reported Q3 2026 revenue of $411.2 million, up 2.3% reported and 2.5% organically, with GAAP EPS of $0.19 and adjusted EPS of $0.59 versus $0.54 a year ago.
Results included roughly $7 million of revenue lost to flood damage at the Cincinnati facility; Specialty Surgery grew 4.2% organically while Tissue Reconstruction declined 2.2%.
The company generated $96.0 million of operating cash flow, cut net debt to $1.5 billion (3.8x leverage), and completed a $2.1 billion refinancing including $450 million of 9.5% senior secured notes due 2033.
FY26 guidance was maintained at $1.634B-$1.654B revenue and $2.30-$2.40 adjusted EPS, but Q4 is guided to negative organic growth of -5.1% to -0.4%, with higher refinancing interest expense near the top of the 100-200bp range.
• 11d ago AI analysis › Press Release ⚠ 2
Integra Announces Completion of Refinancing Transactions
Integra LifeSciences closed a private offering of $450.0 million of 9.500% senior secured notes due 2033 and amended its credit facility to an overall size of approximately $1.65 billion.
The amended Credit Facility comprises a $600 million five-year revolver, a $600 million five-year term loan A, and a $450 million seven-year term loan B. Proceeds were used together with Credit Facility borrowings to refinance the existing credit facility and pay related fees.
The 9.500% coupon on the new notes points to elevated borrowing costs for the medtech, though the deal extends maturities and removes near-term refinancing risk.
• 13d ago AI analysis › Press Release
Integra LifeSciences to Highlight ENT and Instruments Portfolios and Sponsor New Clinical Research Presentations at AAO-HNSF 2026 Annual Meeting
Integra LifeSciences will showcase its ENT and surgical instruments portfolios at the AAO-HNSF 2026 Annual Meeting in Los Angeles, October 17-20, including ACCLARENT AERA, TruDi Navigation, and RELIEVA SPINPLUS.
The company is sponsoring the Otosclerosis Study Group, through which Dr. Seilesh Babu will present new investigator-initiated research on Eustachian tube balloon dilation in chronic ear disease surgery.
The release is a marketing/awareness item with no new financial results or regulatory events; ACCLARENT AERA's pediatric FDA clearance dates to December 2023.
• 16d ago AI analysis › Press Release ⚠ 1
Integra Announces Pricing of Senior Secured Notes
Integra LifeSciences priced $450 million of 9.500% senior secured notes due 2033, sold to qualified institutional buyers under Rule 144A and Regulation S.
Proceeds, together with borrowings under new credit facilities, will refinance existing credit facilities and pay related fees, with closing expected on or about October 19, 2026.
The 9.5% coupon is well above investment-grade levels, signaling elevated debt-service costs; the deal is refinancing rather than new leverage, so near-term impact is limited.
• 23d ago AI analysis › Press Release
Integra LifeSciences to Host Third Quarter 2026 Financial Results Conference Call on October 21, 2026
Integra LifeSciences will release third quarter 2026 financial results on Wednesday, October 21, 2026, before the market opens.
Management will host a conference call at 8:30 a.m. ET the same day, with a live webcast and replay available on the company's investor relations website.
The notice contains no financial results or guidance; it is purely a scheduling announcement.
• 26d ago AI analysis › Press Release ⚠ 5
Integra LifeSciences Announces Preliminary Third Quarter Results and Updates Full-Year 2026 Guidance
Integra LifeSciences preannounced preliminary Q3 2026 results of approximately $410-412 million in revenue and adjusted EPS of $0.55-$0.59, hurt by the July flooding at its Cincinnati facility.
The company cut full-year 2026 guidance, lowering revenue to $1.634-1.654 billion and adjusted EPS to $2.30-$2.40 from prior ranges of $1.654-1.695 billion and $2.40-$2.50.
Flooding reduced Q3 revenue by roughly $7 million and is expected to cut Q4 revenue by $15-20 million, with full manufacturing recovery not expected until Q2 2027.
Offsetting the cut, Integra expects more than $85 million of Q3 operating cash flow, roughly $190-200 million for the year, and says insurance recoveries should mitigate a substantial portion of the earnings impact.
• 0mo ago AI analysis › Press Release ⚠ 2
Integra LifeSciences Announces Launch of $600 Million Senior Secured Term Loan B
Integra LifeSciences launched a proposed $600 million seven-year Senior Secured Term Loan B as part of a broader refinancing of its capital structure.
Proceeds, together with other financing sources, will refinance existing indebtedness and pay associated fees, extending maturities and preserving flexibility.
Completion, final size, terms, and pricing remain subject to market and customary conditions, with no assurance of execution.
• 0mo ago AI analysis › Press Release
Integra LifeSciences Announces 100th Patient Enrolled in AERA® Pediatric Registry
Integra LifeSciences enrolled the 100th patient in the AERA Pediatric Registry, one-third of the planned 300-patient enrollment.
The registry, launched in July 2025, generates real-world evidence for the AERA Eustachian Tube Balloon Dilation System in children ages eight and older, which received FDA clearance for its pediatric indication in December 2023.
Executives framed the milestone as reinforcing Integra's commitment to the ENT market; the news has no near-term financial impact.
• 1mo ago AI analysis › Press Release
Integra LifeSciences Marks 20 Years of CUSA® Technology with Liver Surgery Education at ACS Clinical Congress 2026
Integra LifeSciences is marking 20 years of CUSA technology with surgeon-led liver surgery education at the ACS Clinical Congress 2026, September 26-29 in Washington, D.C.
Programming features the CUSA Clarity Ultrasonic Surgical Aspirator System and MicroFrance laparoscopic instruments, with presentations from liver surgeons Goro Honda and Adnan Alseidi.
The release is promotional in nature with no new financial, regulatory, or clinical data; roughly 800,000 people are diagnosed with liver cancer worldwide each year per cited American Cancer Society statistics.
• 1mo ago AI analysis › Press Release
Integra LifeSciences to Present at the 2026 Wells Fargo Healthcare Conference and the 2026 Morgan Stanley Healthcare Conference
Integra LifeSciences announced that its executives will present at two upcoming healthcare investor conferences in September 2026.
CFO Lea Knight and Chief Commercial Officer Michael McBreen will present at the Wells Fargo Healthcare Conference on September 9 at 2:15 p.m. ET, while Chairman and CEO Stuart Essig will present at the Morgan Stanley Healthcare Conference on September 15 at 4:05 p.m. ET.
Live webcasts will be available on the company's investor relations website; the release contains no financial updates, guidance, or other corporate news.
• 1mo ago AI analysis › Press Release ● Major ⚠ 3
Integra LifeSciences Reports Second Quarter 2026 Financial Results
Integra LifeSciences reported Q2 revenue of $418.8 million, up 0.8% year-over-year, with organic growth of 0.7%. Adjusted EPS increased to $0.56 from $0.45 in the prior year, driven by gross margin expansion to 61.3%.
The company lowered its reported revenue guidance to $1.654 billion to $1.695 billion due to foreign exchange impacts but reaffirmed its full-year organic growth outlook of 0.8% to 3.3% and adjusted EPS guidance of $2.40 to $2.50.
Operational milestones include the initiation of production at the Braintree facility to support the Q4 SurgiMend relaunch. Net debt stood at $1.6 billion with a leverage ratio of 4.1x.
• 3mo ago AI analysis › Press Release
Integra LifeSciences to Host Second Quarter 2026 Financial Results Conference Call on July 29, 2026
Integra LifeSciences will release its second quarter 2026 financial results on Wednesday, July 29, 2026, before the market opens.
Management is scheduled to host a conference call at 8:30 a.m. ET on the same day to discuss the quarterly performance.
A live webcast and replay of the call will be available on the Investors section of the company's website.
• 3mo ago AI analysis › Press Release
Integra LifeSciences Appoints Topaz Kirlew Chief Regulatory Officer
Integra LifeSciences appointed Topaz Kirlew as corporate vice president and chief regulatory officer, elevating her from the interim role she held over the past several months.
Kirlew will lead the company's global regulatory affairs organization, overseeing strategy, compliance, submissions, and transformation initiatives worldwide.
She brings more than 35 years of experience in the healthcare and medical technology industry, having previously held leadership roles at Danaher Corporation and Apyx Medical.
• 4mo ago AI analysis › Press Release
Integra LifeSciences Announces Key Executive Appointments
Integra LifeSciences reshuffled its commercial leadership, appointing Robert T. Davis Jr. as EVP of Tissue Reconstruction and Distributed Technologies and Harvinder Singh as EVP and President of Specialty Surgery.
Christopher Kilburn-Peterson was promoted to corporate VP and president of the Tissue Reconstruction division, reporting to Davis, after serving as SVP and GM of Acclarent.
The changes follow Mike McBreen's appointment as CCO and aim to align the international business under his organization to drive long-term growth.
• 4mo ago AI analysis › Press Release ⚠ 3
Regenerative Medicine’s Next Chapter: Inside the Race to Make the Body Rebuild Itself
This sector analysis, issued on behalf of Conexeu Sciences Inc., forecasts the regenerative medicine market growing to over US$100 billion within a decade, driven by demographic trends and advancements in tissue engineering.
Conexeu is described as an early-stage, pre-revenue company utilizing a proprietary collagen-based ECM platform known as CXU™, having commenced trading on the Nasdaq in May 2026.
The article compares Conexeu to established public peers like Integra LifeSciences and Vericel, while cautioning investors regarding the regulatory and reimbursement risks inherent in the sector.
• 4mo ago AI analysis › Press Release ⚠ 3
The Quiet Revolution in Regenerative Medicine: From Replacing Tissue to Rebuilding It
Conexeu Sciences reports transferring standardized formulation methods to its CDMO and advancing manufacturing scale-up activities for its lead wound-care device candidate.
The company is preparing a 510(k) premarket notification targeted for the first quarter of 2027, supported by prior FDA pre-submission feedback through the Q-Submission process.
Development of the CXU™ platform includes a preclinical breast matrix program in collaboration with Wake Forest Institute for Regenerative Medicine, targeting broader applications beyond wound care.
• 4mo ago AI analysis › Press Release
Integra LifeSciences to Present at the 2026 Truist Securities MedTech Conference
Integra LifeSciences announced that Bob Davis, EVP and President of Tissue Reconstruction, will present at the 2026 Truist Securities MedTech Conference.
The presentation is scheduled for June 16, 2026, at 3:00pm ET and will be available via live webcast on the company's investor relations website.
This is a standard investor relations update with no new operational or financial disclosures.
• 4mo ago AI analysis › Press Release ⚠ 3
A Fresh FDA Catalyst Is Putting Regenerative Wound Care in Focus
Conexeu Sciences is advancing its lead CXU wound-care program into manufacturing scale-up and regulatory preparation, targeting a 510(k) submission in Q1 2027.
The company has transferred standardized formulation methods to a CDMO and is producing representative materials for analytical, biocompatibility, and sterilization testing.
This operational progress marks a transition from research-stage development to regulatory-execution activities, supported by prior FDA pre-submission feedback.
• 4mo ago AI analysis › Press Release
Integra LifeSciences to Present at the 2026 Jefferies Global Healthcare Conference
Integra LifeSciences CFO Lea Knight will present at the 2026 Jefferies Global Healthcare Conference on June 3, 2026, at 10:30am ET.
A live webcast of the presentation will be available on the company's investor relations website.
The announcement contains no new financial results, guidance updates, or strategic disclosures.
• 4mo ago AI analysis › Press Release
Integra LifeSciences to Present at the BofA Securities 2026 Health Care Conference
globenewswire.com • 5mo ago Press Release ⚠ 3
Integra LifeSciences Reports First Quarter 2026 Financial Results
Integra LifeSciences reported Q1 2026 revenue of $391.9 million, up 2.4% reported and 1.3% organic year-over-year, with adjusted EPS rising to $0.54 from $0.41 in the prior year.
The company raised its full-year 2026 adjusted EPS guidance range to $2.40-$2.50, up from the previous $2.30-$2.40, while reaffirming its revenue guidance of $1.662 billion to $1.702 billion.
Management changes included the appointment of Stuart Essig as CEO and Michael McBreen as CCO, while operational progress included improved adjusted EBITDA margins of 19.4% and advancements at the Braintree manufacturing facility.
• 5mo ago AI analysis › Press Release
Integra LifeSciences Announces Leadership Transition
Integra LifeSciences appointed Stuart M. Essig as President and CEO, effective May 1, 2026, succeeding Mojdeh Poul who is pursuing other opportunities.
Essig, who has served as Chairman since 2012 and was previously CEO from 1997 to 2012, will continue as Chairman and the Board confirmed he is not an interim replacement.
Additionally, Michael McBreen was appointed to the newly created role of Chief Commercial Officer to elevate commercial focus and execution.
• 5mo ago AI analysis › 
